Etanercept biosimilar (Mylan)

依那西普生物类似药 (Mylan)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEtanercept biosimilar (Mylan)
Drug Alias Name依那西普生物仿制药 (YL Biologics)NepextoYLB-113
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor βTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisArthritis, RheumatoidArthritis, Juvenile +[6] 
Global Approved IndicationsPlaque psoriasisArthritis, RheumatoidArthritis, Juvenile +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2020/05/20
Country/TerritoryEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesLupin LtdMylan Nv
China Registration ClassN/A

Develop Information

Active CompaniesBiosimilar Collaborations Ireland Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisArthritis, RheumatoidArthritis, Juvenile +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB01
Related LinksWikipediaDrugBankKEGG